Mezzion Pharma Co., Ltd.
Develops novel therapeutics for rare diseases, focusing on Fontan circulation.
140410 | KO
Overview
Corporate Details
- ISIN(s):
- KR7140410002
- LEI:
- Country:
- South Korea
- Address:
- 서울특별시 강남구 삼성로 570 석천빌딩 7층, 서울특별시
- Website:
- https://mezzion.com
- Sector:
- Manufacturing
Description
Mezzion Pharma Co., Ltd. is an innovation-driven pharmaceutical company focused on discovering, developing, and commercializing novel therapeutics for rare diseases. The company's primary efforts are concentrated on addressing the unmet medical needs of individuals with a Fontan circulation, a palliative surgical procedure for single-ventricle heart defects. Its lead drug candidate, udenafil, is being advanced as a potential first-to-market treatment to improve the physiology of the Fontan circulation. Mezzion is conducting late-stage clinical development, including a confirmatory Phase 3 trial (FUEL-2), to evaluate the therapy's efficacy in adolescent patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-12-14 00:00 |
주주명부폐쇄기간또는기준일설정
|
Korean | 4.1 KB | ||
| 2020-12-11 00:00 |
[기재정정]투자판단관련주요경영사항(유데나필(Udenafil) 신약허가신청(NDA))
|
Korean | 11.7 KB | ||
| 2020-12-07 00:00 |
단일판매ㆍ공급계약체결
|
Korean | 9.4 KB | ||
| 2020-11-27 00:00 |
기타경영사항(자율공시)(제 2회차 사모신주인수권부사채 취득 후 재매각)
|
Korean | 9.3 KB | ||
| 2020-11-16 00:00 |
분기보고서 (2020.09)
|
Korean | 882.1 KB | ||
| 2020-11-05 00:00 |
기타경영사항(자율공시)(제2회차 사모신주인수권부사채 취득 후 일부 재매각)
|
Korean | 9.2 KB | ||
| 2020-08-31 00:00 |
[기재정정]투자판단관련주요경영사항(유데나필(Udenafil) 신약허가신청(NDA))
|
Korean | 13.8 KB | ||
| 2020-08-31 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 23.5 KB | ||
| 2020-08-14 00:00 |
본점소재지변경
|
Korean | 5.3 KB | ||
| 2020-08-14 00:00 |
반기보고서 (2020.06)
|
Korean | 864.5 KB | ||
| 2020-07-01 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 23.5 KB | ||
| 2020-06-30 00:00 |
투자판단관련주요경영사항(유데나필(Udenafil) 신약허가신청(NDA))
|
Korean | 7.9 KB | ||
| 2020-05-15 00:00 |
분기보고서 (2020.03)
|
Korean | 823.7 KB | ||
| 2020-05-07 00:00 |
주식매수선택권부여에관한신고
|
Korean | 13.0 KB | ||
| 2020-05-04 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 23.5 KB |
Automate Your Workflow. Get a real-time feed of all Mezzion Pharma Co., Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Mezzion Pharma Co., Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Mezzion Pharma Co., Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
